Role of Protein Kinase C β and VEGF Receptor in Malignant Pleural Mesothelioma
Author Information
Author(s): Loganathan Sivakumar, Kanteti Rajani, Siddiqui Shahid S., El-Hashani Essam, Tretiakova Maria, Vigneswaran Hari, Cervantes Gustavo, Natarajan Viswanathan, Husain Aliya N., Vokes Everett E., Kindler Hedy L., Salgia Ravi
Primary Institution: University of Chicago
Hypothesis
Can the inhibitors enzastaurin and KRN633 effectively target PKC-β and VEGFR-2 in malignant pleural mesothelioma?
Conclusion
Enzastaurin is more effective than KRN633 in killing malignant pleural mesothelioma cells, and both can be used to screen for new cancer treatments using C. elegans.
Supporting Evidence
- Enzastaurin treatment led to significant loss in viability of VEGF-induced cell proliferation.
- PKC-β1 and VEGFR-2 were overexpressed in MPM cell lines and tumor tissues.
- Combination treatment of enzastaurin and KRN633 showed additive effects on cell viability.
- C. elegans treated with enzastaurin exhibited clear phenotypic changes.
- VEGF is a critical factor in tumor growth and metastasis.
- Enzastaurin effectively suppressed phosphorylation of PKC-β and AKT.
- High expression of VEGFR-2 and PKC-β was observed in malignant mesothelioma samples.
- Enzastaurin is a selective inhibitor of PKC-β with high specificity.
Takeaway
This study shows that a drug called enzastaurin can help kill cancer cells in a type of lung cancer called malignant pleural mesothelioma, and scientists can use tiny worms to test new cancer treatments.
Methodology
The study used MPM cell lines, control cells, and archived tumor samples to assess protein expression and the effects of enzastaurin and KRN633 on cell viability and signaling.
Limitations
The study primarily focuses on in vitro results and may not fully represent in vivo responses.
Participant Demographics
The study included 42 tumor samples, with 29 epithelioid and 9 sarcomatoid types.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website